Metagenomi Inc. is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox. Metagenomi Inc. is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | $52.29M |
| Net Income (Most Recent Fiscal Year) | $-78.06M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.17 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.38 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -291.26% |
| Net Margin (Trailing 12 Months) | -287.06% |
| Return on Equity (Trailing 12 Months) | -43.19% |
| Return on Assets (Trailing 12 Months) | -31.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.42 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.53M |
| Free Float | 30.85M |
| Market Capitalization | $67.18M |
| Average Volume (Last 20 Days) | 0.44M |
| Beta (Past 60 Months) | 0.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |